Lineage Cell Therapeutics (LCTX) is set to release its quarterly earnings on Thursday, November 14th. Analysts predict a loss per share of $0.04, but investors will be looking for positive guidance and an indication of the company’s future trajectory. This article provides a comprehensive analysis of Lineage Cell Therapeutics’s past performance, market sentiment, and key financial metrics, offering insights into what investors can expect from the upcoming earnings announcement.